Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Last trade$0.4789
Day change+$0.0089 (+1.89%)
Day range$0.4652 – $0.492
Volume478,805
Market cap$24M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$23.64M
Price / earnings
—
Price / book
0.41×
Price / sales
—
EV / sales
—
EV / EBITDA
0.53×
Profitability
Earnings per share
-$0.84
Return on assets
-42.17%
Return on equity
-72.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.91×
Quick ratio
1.91×
Cash ratio
1.12×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.13M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FLNA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$7.41M
$6.09M
$6.62M
Research and development
$3.87M
$3.3M
$4.54M
Total operating expenses
$11.27M
$9.39M
$11.17M
Operating income
-$11.27M
-$9.39M
-$11.17M
Interest expense
$520K
$747K
$789K
Income before taxes
-$10.73M
-$8.6M
-$10.33M
Income taxes
$0
$0
$0
Net income
-$10.73M
-$8.6M
-$10.33M
Net income attributable to common shareholders
-$10.73M
-$8.6M
-$10.33M
EBITDA
-$11.06M
-$9.15M
-$10.93M
Basic earnings per share
-$0.22
-$0.18
-$0.21
Diluted earnings per share
-$0.22
-$0.18
-$0.21
Recent news
Company coverage with links to the original publishers.
Filana Therapeutics (NASDAQ: FLNA), a biotechnology company developing therapies for TSC-related epilepsy, announced that its management team will participate in the 2026 Maxim Growth Summit scheduled for October 12-14, 2026 in New York. The company will engage in one-on-one meetings at the event.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.